Genmab AS (NAS:GMAB)
$ 26.82 0.33 (1.25%) Market Cap: 17.03 Bil Enterprise Value: 14.84 Bil PE Ratio: 22.15 PB Ratio: 3.69 GF Score: 92/100

Genmab A/S at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 03:00PM GMT
Release Date Price: $42.83 (+4.13%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning and good afternoon. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, it's my pleasure to introduce this Genmab presentation with CEO, Jan van de Winkel, as part of the JPMorgan Healthcare Conference. So today, we have a 20-minute presentation from Jan and then 20 minutes for questions. And then we'll also have CFO, Anthony Pagano, joining us as well. And you can immediately start registering your questions. (Operator Instructions) And then I'll be reading out those questions in the Q&A segment.

So with that said, I'd like to welcome Jan to the conference, and I'm looking forward to the presentation.

Jan G.J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

Thank you, James. It's a pleasure to join you once again, albeit virtually, at the Annual JPMorgan Healthcare Conference as we kick off 2021. Slides from today's presentation will be available for download on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot